Human Genetics Market size was valued at USD 32.4 billion in 2024 and is projected to reach USD 141.7 billion by the end of 2037, rising at a CAGR of 12% during the forecast period, i.e., 2025-2037. In 2025, the industry size of human genetics is assessed at USD 36.3 billion.
Human genetics adoption is gaining traction due to advancements in gene sequencing technologies and an increasing need for personalized health solutions. Genetic testing permits early diagnosis, evaluation of risk, and treatment approaches for various life-threatening diseases, including some rare diseases and cancers. In July 2023, Novartis Espana partnered with DBGen Ocular Genomics to deliver genetic testing services for retinitis pigmentosa and Leber congenital amaurosis. Such collaborations highlight the demand for precision diagnostics in human genetics market. The engagement in such partnerships underlines the commitment of industry players to continuous innovation. This also opens up prospects for further growth, as governments and private investors are continually investing in genetic research and infrastructure.
Government support for genetic testing and personalized medicine creates more scope for players in the human genetics market. Many governments fund national genomic initiatives to study population-specific genetic information, which could help achieve better results in public health and ensure innovative healthcare. As governments continue to emphasize funding in healthcare research and develop policies that favor genetic advancements, the growth in the global human genetics industry is expected to be sustained.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
12% |
|
Base Year Market Size (2024) |
USD 32.4 billion |
|
Forecast Year Market Size (2037) |
USD 141.7 billion |
|
Regional Scope |
|
Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment)
The diagnostics & treatment segment is expected to hold a share of 46.7% through 2037 due to the growing demand for precise diagnosis and personalized treatment options. This is attributed to the advancement of genetic testing, which provides essential insights into patient management. In July 2023, Quest Diagnostics launched Genetic Insights, which provides health reports tailored to an individual's genes, further cementing the need to enable early detection and preventive care in this segment. This trend reflects an increasing role of diagnostics in improving healthcare outcomes.
Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others)
In human genetics market, Non-Invasive Prenatal Testing (NIPT) segment is set to capture revenue share of over 35% by 2037 due to the growing demand for safe prenatal diagnosis. NIPT facilitates early detection of genetic disorders in the fetus, offering vital importance in prenatal care. For instance, in July 2023, Optical Genome Mapping, an advanced technology for next-generation genetic testing, was introduced by a team of scientists from the Centre for Cellular and Molecular Biology, India. This development underlines the increase in the usage of complex genetic testing methodologies, thereby driving the demand for NIPT during the forecast period.
Our in-depth analysis of the human genetics market includes the following segments:
|
Application |
|
|
Test |
|
North America Market Analysis
North America in human genetics market is set to account for around 44% revenue share by 2037, owing to its established healthcare infrastructure and high demand for personalized medicine for genetic testing. There is a strong concentration on precision health and preventive genetic testing activities, hence driving substantial growth in this region. Initiatives taken by governments and favorable reimbursement policies widen access to genetic testing. This lays a higher footing for healthcare and technology to continue promoting North America's leadership in genetics.
The U.S. is leading in genetic testing and precision medicine due to favorable regulatory settings and massive investments in genomic research. In March 2023, a report by Alnylam Pharmaceuticals, Inc. noted that its RNAi therapeutics had benefited more than 2,500 patients, underlining commitments within the U.S. toward state-of-the-art genetic therapies. As a result, such an adoption level places the U.S. among the leading countries in human genetics, particularly in RNA-based treatments.
The human genetics market in Canada is rising at a considerable pace due to government support for research, in addition to individual interest in genetic testing as a form of preventive care. For example, Health Canada advocates for the adoption of genetic diagnostics, making Canada a lucrative market for human genetics solutions. Furthermore, in January 2023, Canada supported the Genome Canada initiative to enhance genetic research, reflecting the country's commitment to precision medicine and innovative healthcare.
Asia Pacific Market Analysis
Asia Pacific human genetics market is expected to showcase growth rate of around 10.5% between 2024 and 2037, due to the support of genomic initiatives by governments and a focus on personalized healthcare. The large population and increasing demand for healthcare create the backdrop for the potential expansion of applications in human genetics. Moreover, newly developed local infrastructure for biotechnology and research calls for accelerated regional innovation. With more nations investing in genomic research, Asia Pacific is likely to emerge as a major contributor to the global market.
The human genetics market in China is supported by the governmental approach to precision medicine with significant investments in genetic research infrastructures. Due to the large population, the country has focused on genomic research to address healthcare challenges. In October 2022, Oxford Nanopore Technologies partnered with 10x Genomics to streamline workflows in genetic testing, reflecting the country's emphasis on advanced diagnostics. Such a focus places China as one of the leading players in Asia Pacific.
The adoption of human genetics in India is being driven by plans for increasing infrastructure for genetic testing and research. Recently, India initiated the Genome Asia 100K project regarding the sequencing of Asian genomes, underlining a commitment toward population-specific genetic understanding. This initiative aligns with country’s goal toward precision medicine development and growth in the human genetics market.
The human genetics market is fiercely competitive and consolidated in nature, with key major players including Myriad Genetics, LabCorp, GE Healthcare, QIAGEN, Agilent Technologies, Thermo Fisher Scientific, Illumina, Promega, Bio-Rad Laboratories, Bode Technology, Orchid Cellmark, and LGC Forensics. These companies focus on extending genetic testing portfolios through continuous technological development, partnerships, and acquisitions. The competitive landscape of the industry depicts a strong focus on precision medicine, wherein leading market players invest intensively in R&D to introduce new genetic tests and personalized healthcare solutions.
In September 2023, Myriad Genetics and Illumina announced two significant deal milestones for the advancement of genomic profiling and homologous recombination deficiency testing. The deal represents the strategic alliance trend among key players to advance specialized genetic diagnostics development. This partnership further highlights the importance of pooling resources and expertise to meet the rising demand for precision medicine, intensifying competition in the global human genetics market.
Here are some leading players in the human genetics market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?